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Abstract 
Background: Precisely targeted nanoparticle delivery is critically important for therapeutic applications. However, 
our knowledge on how the distinct physical and chemical properties of nanoparticles determine tissue penetration 
through physiological barriers, accumulation in specific cells and tissues, and clearance from selected organs has 
remained rather limited. In the recent study, spectral imaging fluorescence microscopy was exploited for precise and 
rapid monitoring of tissue- and cell-type-specific distribution of fluorescent polystyrene nanoparticles with chemically 
distinct surface compositions.
Methods: Fluorescent polystyrene nanoparticles with 50–90 nm diameter and with carboxylated- or polyethylene 
glycol-modified (PEGylated) surfaces were delivered into adult male and pregnant female mice with a single intrave-
nous injection. The precise anatomical distribution of the particles was investigated by confocal microscopy after a 
short-term (5 min) or long-term (4 days) distribution period. In order to distinguish particle-fluorescence from tissue 
autofluorescence and to enhance the detection-efficiency, fluorescence spectral detection was applied during image 
acquisition and a post hoc full spectrum analysis was performed on the final images.
Results: Spectral imaging fluorescence microscopy allowed distinguishing particle-fluorescence from tissue-fluores-
cence in all examined organs (brain, kidney, liver, spleen and placenta) in NP-treated slice preparations. In short-time 
distribution following in vivo NP-administration, all organs contained carboxylated-nanoparticles, while PEGylated-
nanoparticles were not detected in the brain and the placenta. Importantly, nanoparticles were not found in any 
embryonic tissues or in the barrier-protected brain parenchyma. Four days after the administration, particles were 
completely cleared from both the brain and the placenta, while PEGylated-, but not carboxylated-nanoparticles, were 
stuck in the kidney glomerular interstitium. In the spleen, macrophages accumulated large amount of carboxylated 
and PEGylated nanoparticles, with detectable redistribution from the marginal zone to the white pulp during the 
4-day survival period.
Conclusions: Spectral imaging fluorescence microscopy allowed detecting the tissue- and cell-type-specific 
accumulation and barrier-penetration of polystyrene nanoparticles with equal size but chemically distinct surfaces. 
The data revealed that polystyrene nanoparticles are retained by the reticuloendothelial system regardless of surface 
functionalization. Taken together with the increasing production and use of nanoparticles, the results highlight the 
necessity of long-term distribution studies to estimate the potential health-risks implanted by tissue-specific nanopar-
ticle accumulation and clearance.
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Background
Nanoparticles (NPs) are increasingly popular tools with 
widespread industrial, medical and every-day applica-
tions. While the continuous progress in NP production is 
appealing, the escalation of environmental NP pollution 
raises serious health concerns. Despite of world-wide 
efforts, our understanding on the penetration, distribu-
tion, potential accumulation and clearance of various 
NPs in the living body is far from complete.
Several imaging approaches have already been used to 
visualize nanoparticles in vitro or in vivo [1]. Some stud-
ies investigated NP distribution at the whole-body level 
by using magnetic resonance imaging, computed tomog-
raphy, positron emission tomography, or radiolabeling 
techniques [2–4]; whereas other reports focused on the 
subcellular localization of NPs by exploiting transmis-
sion or scanning electron microscopy [5, 6]. Relatively 
few studies attempted to follow the in  vivo distribution 
of distinct types of NPs at the tissue and cellular levels 
[3, 7, 8]. This approach would be important from a medi-
cal perspective, because specific tissues and cells may be 
differentially involved in pathophysiological responses to 
nanoparticle exposure. Moreover, NP-aided drug deliv-
ery seeks to target certain cell types in selected organs, 
while must avoid loading others in order to reduce 
unwanted side-effects [9–11]. To achieve targeted NP 
distribution, it is pivotal to understand the impact of the 
physical and chemical parameters of NPs on their tissue- 
and cell-type-specific accumulation. Yet the availability of 
high-throughput imaging modalities to compare the dis-
tribution of different NPs, is rather limited.
Fluorescence microscopy is generally the method-
of-choice to monitor the cellular and tissue-level dis-
tribution of biologically-relevant fluorescent materials, 
including nanoparticles [12]. However, visualization 
of fluorescent NPs even with high-resolution confocal 
microscopy has been notoriously difficult, because of 
their size (typically being between 1 and 100 nm) is below 
Abbe’s diffraction limit of  ~250  nm. Therefore, fluoro-
chrome-functionalized NPs can only be detected if they 
passively aggregate in body fluids or at biological inter-
faces (e.g. on the blood vessel wall or on the cell surface) 
[13], or if they are actively taken up by cells and are con-
centrated within endocytotic vesicles or lysosomes [14–
16]. Moreover, the detection of fluorescent NPs is further 
hindered by the high autofluorescence of biological sam-
ples [12], which does not allow visualizing small aggre-
gates due to the low signal-to-noise ratio. Increasing 
fluorescent dye concentration on the NP surface may 
lead to enhanced cytotoxicity, whereas encapsulation (in 
“core–shell” nanoparticles) limits dye concentration per 
particle, thereby reducing NP fluorescence intensity [17, 
18]. These constraints stressed the importance of apply-
ing new imaging approaches in the studies on tissue- and 
cell-type-specific NP distribution, and prompted us to 
exploit spectral detection and spectral analysis with the 
aim to overcome the limitations caused by low NP fluo-
rescence versus high tissue autofluorescence.
The in vivo distribution of NPs is influenced by several 
physical and chemical parameters including size, shape, 
core material and surface composition [19]. Importantly, 
NPs readily adsorb various chemical substances from 
their environments due to the highly reactive surface [20, 
21]. The composition and thickness of adsorbed layers 
(the so-called corona) depends on the chemical proper-
ties of both the NP surface and the environment [22–24]. 
Because the corona governs the interaction of NPs with 
biological structures, it plays a decisive role in the tissue- 
and cell-type-specific NP distribution [25, 26]. Moreover, 
as a result of chemical exchange reactions, the corona is 
expected to change with time even within the same tissue 
environment [27, 28]. While NP surfaces are ultimately 
functionalized by the actual environment, this process 
can be regulated by changing the surface charge of NPs 
or by coating the NP with chemically less reactive, hydro-
philic polymers [29]. Polyethylene glycol (PEG) polymers 
with different oligomer-numbers and linear or branching 
chains have been widely used to reduce the chemical reac-
tivity of surfaces [30]. Accordingly, protein adsorption by 
NPs could be reduced by PEGylation, and PEG-coating 
was shown to inhibit the cellular uptake of NPs [31–33], 
as well. In vivo studies demonstrated that PEGylated nan-
oparticles remained longer in the circulation due to their 
reduced attachment to vessel walls and cell surfaces [34, 
35]. These findings together suggested that NPs display-
ing different adsorption-characteristics will show different 
tissue-, and cell-type-specific integration.
To investigate the impact of molecular surface char-
acteristics on the in  vivo tissue penetration and accu-
mulation of otherwise identical NPs, we followed the 
fate of non-toxic polystyrene NPs with carboxylated or 
PEGylated surfaces by spectral imaging fluorescence 
microscopy. Spectral imaging has been used for locali-
zation of quantum dots before [1, 36]. The object of the 
study was to show that spectral imaging is a valuable tool 
to study the biodistribution and subcellular localization 
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of fluorescently labeled NPs with broader emission band-
widths as well.
Results
In vitro characterization of polystyrene nanoparticles
Polystyrene nanoparticles core-labelled with fluorescent 
dyes and surface coated with either carboxyl groups (PS-
COOH) or PEG (PS-PEG) were used throughout this 
study. The physical and chemical parameters of particles 
including size, aggregation properties, and protein adsorp-
tion were thoroughly analyzed. These parameters were 
determined in distinct inorganic or biological environ-
ments, including solutions used during particle handling 
and solutions that mimic the characteristics of body fluids.
Dynamic light scattering (DLS) measurements verified 
the similar size of PS-COOH and PS-PEG NPs (Fig. 1a, 
b): 70.81 ±  21.09 and 68.69 ±  18.68  nm for PS-COOH 
and PS-PEG, respectively; and showed no aggregation of 
particles in distilled water. Transmission electron micro-
scopic (TEM) images showed slight agglomeration of 
dried particles (Fig. 1a, b, insert).
The zeta potential of particles measured by DLS 
in distilled water, showed significant differences: 
−42.1 ± 0.9 mV for PS-COOH and −28.5 ± 1.8 mV for 
PS-PEG NPs. According to hydrodynamic particle size 
distribution, the nanoparticles did not aggregate in dis-
tilled water or in phosphate-buffered saline (PBS) dur-
ing a 96-h assay period (Fig. 1c), indicating that the ionic 
strength of organic material-free physiological saline did 
not induce aggregation of PS-COOH and PS-PEG nano-
particles. In contrast, a time-dependent, heavy particle 
aggregation of both NPs was found in serum-free Dul-
becco’s modified Eagle’s cell culture medium (DMEM), 
which represents an ionic strength similar to PBS, but 
contains various organic compounds including glu-
cose, amino acids, vitamins and non-peptide hormones 
(Fig. 1d). In DMEM, a moderate increase in NP size was 
observed after 4 h, which elevated robustly by the end of 
the 96-h incubation [(hydrodynamic diameters for PS-
COOH: 66.40 ± 0.82 nm (5 min), 116.90 ± 2.10 nm (4 h), 
178.47 ± 17.39 nm (24 h), 851.77 ± 34.27 nm (96 h); for 
PS-PEG: 68.55  ±  0.45  nm (5  min), 115.93  ±  0.60  nm 
Fig. 1 Physical-chemical characterization of polystyrene NPs. Intensity weighted size distribution of carboxylated (a) and PEGylated (b) polystyrene 
nanoparticles measured by dynamic light scattering. Representative TEM images of the particles are shown in the top right panels of each DLS 
plot, scale bars represent 400 nm. c, d Aggregation–agglomeration properties and corona thickening of polystyrene nanoparticles was measured 
by DLS as a change in hydrodynamic size. Particles were incubated in inorganic (c) or biological solutions (d) for 96 h, and the size distribution was 
monitored. Color codes of samples are shown in the figure. Data are presented as mean ± standard deviation (n = 3). Particles showed no aggrega-
tion in distilled water or in PBS during the 96-h assay period (c). In contrast a time-dependent, heavy particle aggregation was found in serum-free 
DMEM (d). Incubation of nanoparticles with 10 % FBS also evoked an immediate size increase, but prevented large-scale aggregation (d). SDS-PAGE 
analysis confirmed the adsorption of serum proteins to both PS-COOH and PS-PEG nanoparticles after 1 h incubation in 10 % serum containing 
MEM (e) and verified reduced protein adsorption of PEG-coated nanoparticles after 24 h incubation (f)
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(4  h), 182.07  ±  30.53  nm (24  h), 559.67  ±  141.11  nm 
(96 h)]. The kinetics of particle-size enlargement is con-
sistent with an immediate deposition of material on par-
ticle surfaces and a large-scale aggregation thereafter. The 
data showed that PEG-coating reduced the aggregation, 
an effect which was evident after long-term incubation 
(Fig. 1d).
The incubation of nanoparticles with 10 % fetal bovine 
serum also evoked an immediate size increase, but pre-
vented large-scale NP aggregation during long-term 
treatment (Fig. 1d). The observation indicated that serum 
components were immediately adsorbed by particle sur-
faces, but instead of cross-linking particles, the protein 
corona could stabilize the suspension of the dispersed 
particles. Additional electrophoresis data further veri-
fied the rapid adsorption of proteins to both PS-COOH 
and PS-PEG nanoparticles (Fig.  1e). PEG-coated nano-
particles, however, exhibited reduced protein adsorption, 
which was evident after 24-h incubation (Fig. 1f ) suggest-
ing that PEGylation makes nanoparticles less prone to 
interactions with the environment. (Raw data of charac-
terization experiments is shown in the Additional file 1).
Physicochemical characterization demonstrated that 
both, protein adsorption on nanoparticle surfaces and 
NP aggregation are influenced by the chemical milieu 
and by the type of surface-coating of NPs.
Spectral imaging fluorescence microscopy visualizes 
in vivo distribution of polystyrene nanoparticles
Previous experiments demonstrated that fresh PS-
COOH or PS-PEG nanoparticle preparations did not 
have toxic effects on several mouse neural cell lines, even 
when applied at a very high concentration (up to 125 µg/
ml) [33]. In accordance with the in  vitro observations, 
single intravenous injection of 33.3 µg/ml PS-COOH or 
PS-PEG nanoparticles did not cause detectable physi-
ological or behavioral changes.
To monitor the in vivo distribution of PS-COOH and 
PS-PEG polystyrene nanoparticles, we developed a spec-
tral imaging fluorescence microscopy based method, 
which could overcome the limitations of nanoparticle 
detection caused by the high autofluorescence of native 
tissues, and could allow analyzing larger samples in less 
time, compared to electron microscopic approaches. 
Using a multidetector array confocal arrangement [Nikon 
A1R Confocal Laser Microscope System equipped with a 
spectral detector unit (Nikon, Shinjuku, Tokyo, Japan)], 
fluorescence intensity was recorded at defined wave-
lengths throughout the investigated spectral range, from 
468 to 548 nm, with a spectral resolution of 2.5 nm. This 
acquisition approach combined with post hoc spectrum 
analysis selectively visualized nanoparticles in various tis-
sues (Fig. 2a). We found that the highest signal-to-noise 
ratio was achieved by illuminating the tissue-embedded 
fluorescent nanoparticles at 457  nm excitation wave-
length (Additional file 2).
Using the optimized imaging settings, the fluorescence 
spectra of PS-COOH and PS-PEG NPs were measured 
in various environments including PBS; PBS comple-
mented with 1 % bovine serum albumin (BSA); mounting 
medium (Mowiol); and seeded onto fixed tissue slices. 
The measured spectra of particles showed parity with 
the spectrum provided by the manufacturer and did not 
vary substantially under different conditions (Fig.  2b). 
Furthermore, the different surface coating had no direct 
effect on the NP fluorescence, PS-COOH and PS-PEG 
nanoparticles displayed identical fluorescence spectra 
(Fig.  2c). For spectral analysis, the autofluorescence of 
particle-free, fixed tissue-sections was used as a negative 
control (Additional file  3), whereas the fluorescence of 
NPs seeded on control tissue sections served as positive 
controls.
Tissue‑ and cell‑type‑specific distribution of PS‑COOH 
and PS‑PEG nanoparticles
To evaluate short-term and the long-term distribution 
of NPs, mice were sacrificed either 5  min after a single 
tail-vein injection, or after a 4-day long survival period. 
In general, all investigated organs including the brain, 
kidney, liver, placenta and the spleen showed different 
amounts of nanoparticles after a single intravenous injec-
tion, and displayed distinct clearing after the 4-day post-
injection period (Table 1).
Five minutes after nanoparticle injection, high abun-
dance of both PS-COOH and PS-PEG NPs were found 
in organs involved in the elimination of toxic products 
from the body, such as the kidney, liver and the spleen. In 
organs protected by complex physiological barriers, such 
as the brain and the placenta, high density of PS-COOH 
NPs was revealed, while PS-PEG NPs were not present 
(Table 1).
The high-resolution of confocal microscopy combined 
with spectral imaging enabled more detailed analysis of 
regional and cellular distribution of nanoparticles in vari-
ous tissues. Notably, aggregated PS-COOH NPs were 
concentrated in large vessels and capillaries within the 
brain, whereas the parenchyma was largely devoid of NPs 
(Fig.  3a, b; Additional file  4). In the placenta, PS-COOH 
NPs, but not PS-PEG NPs were seen in the lacunas 
(Fig. 3c, d), and importantly, neither type of nanoparticles 
was found in embryonic tissues (Additional file 5), indicat-
ing a proper placental barrier function.
In the kidney, both PS-COOH and PS-PEG NPs were 
present in the glomeruli and also in the interstitium 
around the tubuli 5  min after nanoparticle administra-
tion (Fig.  4a, c). Numerous NPs were identified in the 
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Fig. 2 Spectral imaging fluorescence microscopy and full spectrum analysis visualizes in vivo distribution of polystyrene nanoparticles. a Summary 
of the spectral analysis of particle-fluorescence (green) versus tissue-autofluorescene (red) after a single injection of COOH- or PEG-coated poly-
styrene nanoparticles. b, c Emission spectra of nanoparticles measured by spectral imaging fluorescence microscopy. Specimens were excited at 
457 nm and the emitted light was detected in a wavelength range from 468 to 548 nm, with a spectral resolution of 2.5 nm. Spectra of polystyrene 
nanoparticles did not change in different conditions (shown as color-codes in b) or after functionalization (c) compared to the native spectrum 
provided by the manufacturer (represented by the aquamarine color-code in the figures)
Table 1 Biodistribution of polystyrene nanoparticles after intravenous injection. Summary of the distribution of differ-
ently functionalized polystyrene NPs after intravenous injection into mice. Organs were excised 5 min or 4 days after par-
ticles administration
Brain Placenta Kidney Liver Spleen Embryonic tissue
PS-COOH
 5 min + + + + + −
 4 days − − − + + −
PS-PEG
 5 min − − + + + −
 4 days − − + + + −
Page 6 of 14Kenesei et al. J Nanobiotechnol  (2016) 14:55 
liver (Fig. 5b) and in the spleen (Fig. 6a, c), regardless of 
the type of NP surface functionalization. In the spleen, 
NP distribution was mainly restricted to the marginal 
zone, enriched in monocytes/macrophages. Immunocy-
tochemical analysis directly demonstrated the presence 
of both PS-COOH and PS-PEG NPs within the intracel-
lular vesicles of Iba-1-positive phagocytotic cells (Fig. 7).
Four days after nanoparticle administration, PS-
COOH NPs were completely cleared from the brain and 
the placenta and PS-PEG NPs were not found in these 
tissues (Additional file 6). Significant reduction of nano-
particle density was also observed in the kidney. While 
PS-COOH particles were not found in the kidney sec-
tions anymore, a few PS-PEG NPs were still deposited 
within the glomeruli (Fig. 4b, d). In striking contrast, high 
densities of both NPs were found in the liver (Fig.  5c, 
d) and in the spleen (Fig.  6b, d). The regional distribu-
tion of polystyrene nanoparticles did not change during 
the 4-day post-loading period in the liver. Characteristic 
redistribution of NPs was, however, observed within the 
spleen: 4-days after the exposure, NPs were identified in 
the white pulp, regardless of surface functionalization 
(Fig. 7b, d).
Taken together, spectral imaging fluorescence micros-
copy was instrumental in characterizing the penetration 
and accumulation of nanoparticle in different organs. The 
findings also show that differentially-coated nanoparti-
cles exhibit distinct tissue- and cell-type-specific distri-
bution and clearance.
Discussion
To investigate the impact of surface chemical characteris-
tics of NPs in particle-distribution in the living body, flu-
orescently core-labeled polystyrene nanoparticles, with 
different surface characteristics were used. Polystyrene as 
a core material was chosen, because of its stability in bio-
logical solutions, and because ions or toxic compounds 
could not dissolve from it [37]. Polystyrene in bulk mate-
rial is not toxic [38] and our previous in vitro data dem-
onstrated that 50 nm polystyrene particles were not toxic 
to several mouse neural cell lines, when used at con-
centrations up to 125  μg/ml [33]. Particle surfaces were 
Fig. 3 Distribution of polystyrene NPs in the brain and the placenta 5 min after systemic exposure. Spectral images of tissue sections from the 
mouse brain (a, b) and placenta (c, d) 5 min after injection of PS-COOH (a, c) or PS-PEG (b, d) nanoparticles into the tail vein. a′–d′: spectrum 
profiles of ROIs in the corresponding images. The spectrum of each ROI is marked with the same color as it is delineated in the microscopic image. 
Green curves represent particle fluorescence (positive controls); red curve represents tissue autofluorescence (negative control). Scale bars 50 µm
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functionalized either with -COOH− groups presenting 
strong negative surface charge and mediating ionic inter-
actions or with hydrophilic and charge neutralizing -PEG 
chains.
Physicochemical characterization of the particles 
revealed that the applied PS-COOH and PS-PEG parti-
cles could be considered identical in their physicochemi-
cal aspects, except for the chemical reactivity of their 
surfaces. At early time points particles did not show 
significant hydrodynamic size differences in serum con-
taining physiological solutions. Accordingly, PS-COOH 
and PS-PEG particles were expected to similarly influ-
ence the blood flow conditions at the time of intravenous 
administration. The DLS measurements demonstrated 
that particles were stabilized in serum-containing flu-
ids, accordingly large-scale aggregate formation was not 
expected in the circulation, either. The 50–90 nm particle 
size-range promised several advantages. Particles were 
comparable in size with natural assemblies of protein 
complexes, thus were not expected to block circulation 
in the applied concentration. On the other hand, particles 
were big enough not to be excreted rapidly by the kidney, 
which is known to retain proteins and particles larger 
than 10 nm [4]. Fluorescence spectrum of particles was 
identical for the two particles regardless of surface func-
tionalization, and was not affected by different environ-
mental conditions, ranging from the dry state to protein 
containing solutions.
Taken together, their stable spectra, identical hydrody-
namic size, and the expected similar effect on flow condi-
tions, PS-COOH and PS-PEG nanoparticles represented 
ideal tools to investigate the effect of distinct surface 
characteristics on in vivo accumulation.
Visualization of fluorescent nanoparticles even with 
high-resolution confocal microscopy is hindered by 
the size of nanoparticles and by the high autofluo-
rescence of biological samples [12]. The intensity of 
particle fluorescence depends on the amount of fluo-
rescent dye or on the properties of the core material. 
In physiological experimentation the use of poten-
tially inert particles labelled with non-toxic signaling 
compounds is critically important. Therefore, interest 
Fig. 4 Distribution and accumulation of polystyrene nanoparticles in the kidney. Spectral images of adult mouse kidney sections 5 min (a, c) and 
4 days (b, d) after injection of PS-COOH (a, b) or PS_PEG (c, d) nanoparticles through the tail vein. a′–d′: spectrum profiles of ROIs in the cor-
responding images. The spectrum of each ROI is marked with the same color as it is delineated in the microscopic image. Green curves represent 
particle fluorescence (positive controls); red curve represents tissue autofluorescence (negative control). Scale bars 50 µm
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was turned to polymer nanoparticles which encapsu-
late fluorescent dyes. While the covalent embedding 
of the dye into the core-material prevents dissolution, 
the amount of “in-core” dye is limited and hinders the 
fluorescence detection.
In the present study, spectral imaging fluorescence 
microscopy was used to overcome the limitations caused 
by high autofluorescence and low particle fluorescence. 
Spectral image acquisition combined with spectrum 
analysis could reliably detect fluorescent polystyrene 
nanoparticles at the tissue- and cellular level.
The distribution of PS-COOH and PS-PEG nanoparti-
cles was investigated at two time points, 5 min and 4 days 
after particle loading. Initial distribution of particles 
could not be revealed by histological methods because 
of the high heart rate (300–800 beats/min) and 20–45 µl 
stroke volume of mice resulting in an average 20 ml/min 
cardiac output [39]. The 5  min exposure allowed inves-
tigating short-term tissue distribution of particles after a 
single injection and comparison to a longer term (4 day) 
distribution.
Five minutes after NP-injection, significantly more PS-
COOH then PS-PEG particles were found at the walls of 
brain vessels and in the placenta. As it was expected [32, 
33, 40], PEGylation inhibited the attachment of particles 
to biological interfaces, while PS-COOH particles could 
interact with vessel walls and cell surfaces. On the other 
hand, PEGylation could not prevent the active uptake of 
PS-PEG NPs by professional macrophages [41, 42]. We 
found a remarkable accumulation of both PS-COOH and 
PS-PEG nanoparticles in the kidney, liver and the spleen, 
e.g. in organs responsible for elimination of particulate 
polluting agents from the circulation.
Particles were never seen in embryonic tissues indi-
cating a proper placental barrier function against poly-
styrene nanoparticles, as it was shown also for human 
placenta [43].
After 4 days, the particles were completely cleared from 
the vessels of the brain and the placenta, but were accumu-
lated in the liver and the spleen. The presented study did 
not aim and allow analyzing the renal clearance of the par-
ticles. The persisting presence of PS-PEG particles in the 
glomeruli, however, suggested that particles were accumu-
lated by intraglomerular mesangial cells known to phago-
cytose contaminating particles, mesangial matrix material 
and cell debris [44]. In the spleen, several particles were 
translocated from the marginal zones into the white pulp 
during the 4-day post-injection period. Our observations 
on the storage and translocation of these nanoparticles are 
worthy of further consideration, since they may suggest a 
Fig. 5 Accumulation of polystyrene nanoparticles in the liver. Traditional fluorescence microscopic images of sections made from livers of non-
treated (a) and NP-injected (b, c, d) adult mice. Animals were sacrificed 5 min (b) and 4 days (c) after intravenous injection of PS-COOH and 4 days 
after injection of PS-PEG (d) polystyrene nanoparticles. Particle fluorescence is shown in green, and bisbenzimide nuclear staining in blue. Scale bars 
100 µm
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method through which compounds on particle surfaces 
can be presented to the lymphocytes of the marginal zone 
and the white-pulp [45] and thus manipulate the initiation 
of adaptive immune responses. Regarding the large-scale 
material adsorption by NP surfaces including LPS contam-
ination [33], the inflammation-initiating effects of “harm-
less” NPs should not be neglected.
The observations indicate that middle-sized (50–
90 nm) non-biodegradable nanoparticles which are cap-
tured by macrophages in the spleen and the liver or even 
in the kidney interstitium, cannot be easily removed from 
the body. Regarding the fact that material of dying cells 
will be ingested by neighboring phagocytes, the question 
can be raised whether such particles can be cleared at 
all. Long-term accumulation and limited clearance may 
cause problems if repeated nanoparticle loading is con-
sidered, even if the acute single dose of potentially “harm-
less” particles is low. Considering the continuous growth 
of the production and use of nanoparticles, together with 
the consequent increase in environmental nanoparticle 
pollution, the long-term fate of nanoparticles in exposed 
organisms needs further thorough studies. These con-
cerns stress the importance of high-throughput imaging 
modalities which help to perform distribution studies of 
tissue- and cell-type-specific NP accumulation. Spectral 
imaging fluorescence microscopy provides technological 
tools to monitor the penetration, distribution and accu-
mulation of fluorescently labeled NPs in various tissues 
with high accuracy and in a time-frame which cannot be 
achieved with electron microscopy.
Conclusions
In this work, the in vivo distribution of 50–90 nm poly-
styrene nanoparticles with distinct surface characteris-
tics was investigated using spectral imaging fluorescence 
microscopy. Spectral imaging combined with post hoc 
spectrum analysis allowed visualizing nanoparticles in 
various tissues and helped to overcome the limitations 
caused by the high autofluorescence of native tissues. As 
an additional advantage, the method allowed analyzing 
larger samples in less time, compared to electron micro-
scopic approaches.
Fig. 6 Distribution and accumulation of PS nanoparticles in the spleen. Spectral images of mouse spleen sections after a single intravenous 
injection of carboxylated (a, b) or PEGylated (c, d) polystyrene nanoparticles, 5 min (a, c) and 4 days (b, d) after exposure. Red arrows indicate 
translocated particles to the white pulp during the 4-day after exposure period. a′–d′: spectrum profiles of ROIs in the corresponding images. The 
spectrum of each ROI is marked with the same color as it is delineated in the microscopic image. Green curves represent particle fluorescence (posi-
tive controls); red curves represent tissue autofluorescence (negative controls). Scale bars 100 µm
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Analyses of the body-distribution of carboxylated or 
PEGylated polystyrene NPs indicated proper barrier-
functions for the blood–brain-barrier and the placenta. 
While NPs were stuck in the brain vessels and the lacu-
nas of the placenta, barriers completely prevented the 
penetration of particles into the brain parenchyma and 
embryonic tissues. Particles with both surface function-
alization were accumulated in the reticuloendothelial 
organs. While PEGylation reduced short-term attach-
ment of particles to vessel walls, it did not prevent 
accumulation in the liver and the spleen or in the intra-
glomerular mesangium.
The accumulation and long-term storage of nanopar-
ticles in the reticuloendothelial systems rise important 




Nominal size of 50–70  nm carboxylated and PEGylated 
(MwPEG = 300 g/mol) nanoparticles made from “Yellow” 
fluorochrome-labelled polystyrene, were obtained from 
Spherotech Inc. (Lake Forest, IL, USA). (Fluorescence 
spectrum provided by the manufacturer for these “yel-
low” particles [46]). Concentration of the stock suspen-
sions was 10 mg/ml.
Size and zeta-potential of nanoparticles were measured 
by ZetasizerNano ZS90 (Horiba Instruments Inc., Irvine, 
Fig. 7 PS-NPs are associated with the marginal zone monocytes/macrophages, identified by Iba-1 staining. Immunohistochemical staining for the 
spleen macrophages, stained with anti-Iba-1 antibody (a red), and carboxylated PS-NPs (b green) 4 days after a single intravenous injection of nano-
particles. Merged image (c) shows that residual nanoparticles (green) are co-localized with Iba-positivity of marginal zone macrophages (red). Scale 
bars 250 µm. Confocal images of spleen sections from non-treated (d) or PS-PEG-injected (e, f) mice. Samples were collected 5 min (e) or 4 days (f) 
after exposure to PS- PEG, and were stained for Iba-1. The sample from non-treated animal (d) serves also as staining control. Enlarged areas of the 
boxed regions in e and f, show the presence of PS-PEG NPs in Iba-1 positive phagocytotic cells. g The spectra of ROIs indicated the presence of PS-
PEG NPs on images of both, 5-min and 4-day samples. The spectrum of each ROI is marked with the same color as it is delineated in the microscopic 
image. Fluorescence spectra of ROIs were compared against spectrum of tissue autofluorescence (red curves as negative controls) and particle 
fluorescence (green curves as positive controls). Scale bars 20 µm
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CA). For dynamic light scattering analysis 0.01  mg/ml 
nanoparticle suspensions were measured using a 633 nm 
He–Ne laser. Zeta-potential measurements were carried 
out at 25 °C using a folded capillary cell (DTS1070, Mal-
vern Instruments, Worcestershire, United Kingdom).
Size and shape of nanoparticles were confirmed by 
transmission electron microscopy (JEOL JEM 1010, JEOL 
Ltd., Tokyo, Japan) at 80 keV. For TEM analysis, 3 µl ali-
quots of 0.01 mg/ml nanoparticle suspensions in distilled 
water were transferred to and dried on 200 mesh copper 
grids with carbon film.
Particles were stored in sterile MilliQ water and were 
used within 2–3 months after synthesis.
Raw data of characterization experiments is shown in 
the Additional file 1.
Aggregation and protein adsorption of particles 
in biological solutions
Increase in particle diameter was measured by DLS. 
Nanoparticle aggregation was monitored in inorganic or 
biological environments, including solutions used during 
particle handling and solutions that mimic the character-
istics of body fluids. 1 mg/ml carboxylated and PEGylated 
particle preparations were made by 1:10 dilution of stock 
suspensions with distilled water. The suspensions were 
further diluted 1:10 with PBS (pH 7.4), DMEM cell cul-
ture medium (Sigma-Aldrich, St. Louis, MO, USA) or 
DMEM supplemented with 10 % fetal bovine serum (Inv-
itrogen/Gibco, Carlsbad, CA, USA). After 0, 4, 24 or 96-h 
incubation at 37 °C, particle preparations were diluted in 
1:10 with distilled water and the hydrodynamic diameter 
of particles was measured by DLS.
Proteins adsorbed by particles in 10  % fetal bovine 
serum containing minimum essential medium (FBS-
MEM; Sigma-Aldrich, St. Louis, MO, USA) were 
analyzed by SDS-PAGE (Sodium dodecyl sulfate poly-
acrylamide gel electrophoresis). After 1 or 24-h incuba-
tion in 10  % FBS-MEM nanoparticles were sedimented 
by centrifugation (45 min at 20,000×g) and were washed 
with PBS to remove non-bound proteins. Washed NPs 
were resuspended in Laemmli buffer containing 1 % (w/v) 
sodium dodecyl sulfate, and loaded onto 10 % polyacryla-
mide gel. Gel electrophoresis was performed at 130 V for 
about 60 min. The gels were stained with silver staining 
33 kit (Cosmobio Ltd., Tokyo, Japan), according to the 
manufacturer’s instructions.
In vivo experiments
Animal experiments were conducted with the 
approval of the Animal Care Committee of the Insti-
tute of Experimental Medicine of Hungarian Acad-
emy of Sciences and according to the official license 
(No.: 22.1/353/3/2011; exp. date: 4/7/2016) issued by 
National Food Chain Safety Office (http://www.NEBIH.
gov.hu), Hungary.
Male mice (aged 25–30  days) and pregnant female 
mice on the 10th to 15th post conception days were anes-
thetized with a mixture of ketamine (CP-Pharma mbH, 
Burgdorf, Germany) and xylazine (CEVA-PHYLAXIA, 
Budapest, Hungary), 100 and 10  µg/g bodyweight, 
respectively. Nanoparticle stock suspensions (10 mg/ml) 
were diluted 1:30 in PBS and dispersed by sonication. 
Under proper anesthesia, 7  µl/g bodyweight aliquots of 
carboxylated (nCOOH(male)  =  6, nCOOH(pregnant female)  =  6) 
or PEGylated (nPEG(male) = 6, nPEG(pregnant female) = 6) nano-
particle suspensions were introduced into the tail vein. 
Animals were sacrificed by overdose of anesthetics after 
a 5-min or 4-day exposure to the single-injection load-
ing. Various organs including brain, liver, kidney, spleen 
as well as placenta and embryos were removed and fixed 
with paraformaldehyde (8 w/v % in PBS) for 24 h at 4 °C. 
Organs and embryos were collected from animals not 
exposed to nanoparticles, as controls (ncontrol(male)  =  3, 
ncontrol(pregnant female) = 3).
Microscopic evaluation
For microscopic evaluation, 30 or 60 µm thick vibratome 
sections (VT1000S, Leica, Wetzlar, Germany) were made 
from fixed organs.
For immunocytochemical staining, the sections were 
permeabilized and non-specific antibody binding was 
blocked by incubating the sections in PBS containing 
10 % FBS and 0.1 % Triton-X for 2 h. Primary antibod-
ies, anti-Iba-1 goat polyclonal antibodies and anti-clau-
din V rabbit polyclonal antibodies (Abcam; Cambridge, 
UK) were diluted in 1–1000 with PBS-FBS, and the sec-
tions were incubated at 4  °C, overnight. After incuba-
tion, the cells were washed three times (15  min each) 
with PBS and incubated with alexa-594 conjugated sec-
ondary antibodies (1:1000; Molecular Probes, Invitro-
gen, Carlsbad, CA, USA) for 1  h. Slices were mounted 
with mowiol (Sigma-Aldrich, Budapest, Hungary) con-
taining 10  μg/ml bisbenzimide (Sigma-Aldrich) for 
nuclear staining.
Sections were analyzed with a Zeiss Axiovert 200  M 
fluorescence microscope (Zeiss, Jena, Germany) and a 
Nikon A1R Confocal Laser Microscope System equipped 
with a spectral detector unit (Nikon, Shinjuku, Tokyo, 
Japan).
Optimized detection of particles by spectral imaging 
fluorescence microscopy
Fluorescence spectra of NPs were determined in dry and 
in buffer-dispersed particle preparations, as well as in 
contact with fixed tissue sections from control animals by 
spectral imaging fluorescence microscopy. The extrinsic 
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spectra emitted by the particles in contact with the corre-
sponding tissue section from control animals were used 
as positive controls. For negative control, the intrinsic 
autofluorescence spectra of corresponding sections of 
control organs were used (Additional file 3).
For spectral evaluation 457 nm argon ion laser was used 
as excitation source, and the emitted light was detected 
by the spectral detector unit from 468 to 548  nm, with 
a spectral resolution of 2.5  nm. In order to record con-
tinuous spectrum, a 20/80 beam splitter (BS20/80) with 
continuous transmission was used instead of a paired 
dichronic mirror arrangement.
Regions of interest (ROI) were delineated and analyzed 
in comparison with corresponding sections of nanopar-
ticle-treated and non-treated organs. The photocurrent 
intensities detected in the samples at different wave-
lengths (emission spectra in organs of treated animals) 
were plotted against the tissue autofluorescence spec-
tra (negative control) and the spectra of nanoparticles 
seeded on control-tissue (positive control).
Additional files
Additional file 1: Raw results of characterization experiments. PS-NPs 
were incubated with inorganic or biological solutions. After 5-min, 4, 24 or 
96 h incubation size distribution and zeta-potential measurements were 
carried out by a ZetasizerNano ZS90.
Additional file 2: Excitation of fluorophore labelled polystyrene nano-
particles. Nanoparticles were excited at 404, 457, 476 nm wavelengths to 
determine optimal excitation settings. Highest intensity of emitted light 
was reached when samples were excited at 457 nm.
Additional file 3: Intrinsic fluorescence of non-treated tissue sections. 
Spectral images showing autofluorescence of non-treated brain (A), 
placenta (B), kidney (C) and spleen (D) sections. Green curves represent 
particle fluorescence (positive controls); the red curve represents the 
autofluorescence. The autofluorescence spectra were used as negative 
controls for post hoc spectral identification of PS-NPs in the correspond-
ing tissues. A’, B’, C’, D’: spectrum profiles of ROIs in the corresponding 
images. The spectrum of each ROI is marked with the same color as it is 
delineated in the microscopic image.
Additional file 4: Polystyrene NPs in brain vessels 5 min after systemic 
exposure. Fluorescence images of sections made from brain of PS-PEG (A) 
or PS-COOH (B) injected adult mice. Animals were sacrificed 5 min after 
intravenous injection. Sections were stained for Claudin V (red); cell nuclei 
are shown in blue. Scale bars: 50 µm.
Additional file 5: Embryonic tissues were free from nanoparticles 5 min 
after maternal NP-administration. Sections made from mouse embryonic 
(E 15) forebrain cortex (A, B, C) and liver (D, E) 5 min after the injection of 
carboxylated PS nanoparticles into the tail vein of the mother. Cell nuclei 
are stained with bisbenzimide (blue). Representative spectrum images 
(C, E) and spectrum profiles (C’, E’) showed no particles in the embryonic 
brain or liver tissues. Scale bars: 50 µm.
Additional file 6: PS-NP cleared from the brain and the placenta within 
the 4-day post-injection period. Spectral images of sections of mouse 
brain (A, B) and placenta (C, D) 4 days after injection of PS-COOH (A, C) 
or PS-PEG (B, D) nanoparticles into the tail vein of adult mice. A’, B’, C’, D’: 
spectrum profiles of ROIs in the corresponding images. The spectrum 
of each ROI is marked with the same color as it is delineated in the 
microscopic image. Green curves represent particle fluorescence (positive 
controls); red curve represents tissue autofluorescence (negative control). 
Scale bars: 50 µm.
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